DLG4 and Alzheimer disease: In summary, our study provides the first demonstration of the molecular mechanisms underlying elevated seizure response during the early stage of Aβ pathology and introduces PSD-95 as an early biomarker and potential therapeutic target for alleviating seizure attacks in AD.